Exhibit 99.1 Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview - 2023 total net product sales of $726.4 million, reflecting 40% revenue growth. - Fourth quarter DAYBUE™ (trofinetide) net product sales of $87.1 million and full year 2023 net product sales of $177.2 million. - Fourth quarter NUPLAZID® (pimavanserin) net product sales of $143.9 million and full year 2023 net product sales of $549.2 million. SAN DIEGO, CA, February 27, 2024 – Acadia Pharma ...

Core Viewpoint - Acadia Pharmaceuticals is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the earnings report expected on February 27, 2024, which could significantly influence the stock price depending on the actual results compared to estimates [1][2]. Financial Expectations - The consensus estimate for quarterly earnings is $0.32 per share, reflecting a year-over-year increase of +223.1% [2]. - Expected revenues are projected at $223.08 million, representing a 63.4% increase from the same quarter last year [2]. Estimate Revisions - The consensus EPS estimate has been revised down by 2.47% over the last 30 days, indicating a reassessment by analysts [2]. - Acadia's Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -10.08%, suggesting a bearish outlook from analysts [5]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading typically suggests a likely earnings beat, but Acadia's negative Earnings ESP reading complicates predictions for an earnings beat [3][4][6]. - The stock currently holds a Zacks Rank of 3, which does not strongly indicate a likelihood of beating the consensus EPS estimate [5][6]. Historical Performance - In the last reported quarter, Acadia was expected to post a loss of $0.43 per share but reported a loss of $0.40, resulting in a surprise of +6.98% [7]. - Over the past four quarters, Acadia has beaten consensus EPS estimates twice [7]. Conclusion - While Acadia is not positioned as a compelling earnings-beat candidate, investors should consider other factors influencing stock performance ahead of the earnings release [8].

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced two new appointments to its executive team. Jennifer J. Rhodes is joining the company as Executive Vice President, Chief Legal Officer and Secretary, and Kimberly J. Manhard as Senior Vice President, Global Strategic Planning and Execution, both effective immediately. Following a transition period, Austin D. Kim, Executive Vice President, General Counsel and Secretary will be leaving Acadia to pursue other opportunities. ...

Core Insights - The article discusses the late-stage trials of Acadia Pharmaceuticals and Soleno Therapeutics in the treatment of Prader-Willi Syndrome (PWS), highlighting the differences in their development stages and market positions [2][11]. Company Overview - Acadia Pharmaceuticals is an established commercial stage company with a market cap of approximately $4.53 billion as of January 21, 2024, while Soleno Therapeutics is a clinical stage company with a market cap of around $1.33 billion [4][5]. - Acadia's marketed therapies include NUPLAZID and DAYBUE, generating quarterly revenues of approximately $149 million and $67 million, respectively [4]. Product Pipeline - Acadia's PWS candidate therapy, ACP-101, is currently in a Phase 3 study with an estimated completion date in June 2026 [4][9]. - Soleno's PWS therapy, DCCR (diazoxide choline), is the primary focus of the company and is further along in development, with plans to submit a New Drug Application (NDA) for DCCR in mid-2024 [5][10]. Clinical Trials and Results - Soleno's DCCR has shown significant improvements in hyperphagia and other behavioral parameters in its long-term safety extension study (C602), with a highly statistically significant difference compared to placebo [8][10]. - Acadia's ACP-101 is still enrolling patients and lacks a defined timeline for potential filing, putting it behind Soleno's DCCR in terms of development [9]. Market Performance - Soleno's share price experienced significant volatility, with a notable increase following positive results from Study C602, closing at $47.01 as of January 21, 2024 [10]. - Acadia is rated a "Buy" based on its underlying metrics, while Soleno is considered a "Hold" due to its limited pipeline beyond DCCR [11].

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on January 9, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 39,169 shares of common stock and 13,895 restricted stock units (“RSUs”) to eleven new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in a ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D., M.S.P.H. Serge passed away peacefully on December 29, 2023, following a prolonged illness. “Serge” as he was known to friends and colleagues, joined Acadia in 2015 and led Acadia’s Research and Development organization for more than seven years. He played an instrumental role in Acadia becoming a commercial stage company, providing his significan ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Acadia Pharmaceuticals (ACAD) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Ran ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Jessica Tieszen - Associate Director of Investor Relations Albert Kildani - Senior Vice President, Investor Relations & Corporate Communications Steve Davis - Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Doug Williamson - Head of Research & Development Mark Schneyer - Chief Financial Officer Parag Meswani - Senior Vice President: Trofinetide, Rar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 06-1376651 (State of Incorporation) (I.R.S. Employer Identification No ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Jessica Tieszen - Associate Director of Investor Relations Mark Johnson - Vice President of Investor Relations Steve Davis - Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Doug Williamson - Head of Research & Development Mark Schneyer - Chief Financial Officer Kathie Bishop - Head of Rare Diseases and External Innovation Conference Call Participants ...